E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Selected Papers from the International Conference on Coastal Ecology and Marine Biotechnology Dec. 8-10, 2016 Bangkok, Thailand"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (1 July 2017)

Special Issue Editors

Guest Editor
Dr. Antonio Trincone

Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Comprensorio Olivetti, Edificio 70, Via Campi Flegrei 34, I-80078 Pozzuoli, Napoli, Italy
Website | E-Mail
Fax: +39 081 8041770
Interests: biocatalysis; marine enzymes; marine glycosidases; marine biotechnology; oligosaccharides
Guest Editor
Prof. Se-Kwon Kim

Department of Marine Life Science, College of Ocean Science and Technology, Korea Maritime and Ocean University, 727, Taejong-ro, Youngdo-Gu, Busan, 606-91, South Korea
Website | E-Mail
Phone: 82-51-629-7098
Fax: +82 51 629 7099
Interests: marine natural products; marine biotechnology, marine algae; anti-oxidant; anti-HIV; anti-cancer; anti-allergy; anti-Inflammation; marine cosmeceuticals; nutraceuticals and pharmaceuticals

Special Issue Information

Dear Colleagues,

The International Conference on Coastal Ecology and Marine Biotechnology is organized by Asia-Pacific Association of Science, Engineering and Technology (APASET), will be held in Bangkok, Thailand from 8–10 December, 2016. The meeting will bring together the international scientific community and many segments of the biotech industry to provide a platform for exchanging ideas in marine biotechnology, coastal ecology and applications.

This Special Issue will host contributions to the conference related to the marine biotechnology aspects of the conference. In particular, marine microbiology and biotechnology, including genomics and proteomics of marine organisms and marine metagenomics will be expected in "Tools and Methods in Marine Biotechnology", while all aspects related to marine biomolecules are included in "Marine Resource: Research and Applications".

The conference will cover both the basic science, as well as its applications.

Program Chair of the Conference Dr. Se-Kwon Kim and Dr. A. Trincone of the scientific committee organized this Special Issue of Marine Drugs dedicated to this conference, and kindly invite you to participate to this Special Issue.

Dr. Antonio Trincone
Prof. Dr. Se-Kwon Kim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Open AccessArticle Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models
Mar. Drugs 2017, 15(6), 163; doi:10.3390/md15060163
Received: 8 February 2017 / Revised: 27 May 2017 / Accepted: 1 June 2017 / Published: 3 June 2017
PDF Full-text (1274 KB) | HTML Full-text | XML Full-text
Abstract
The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B
[...] Read more.
The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B and the sterol regulatory element-binding protein-1c (SREBP-1c) signaling pathway, which is related to lipid metabolism. Mice were dosed with xyloketal B (5, 10 and 20 mg/kg/d) and atorvastatin (15 mg/kg/d) via intraperitoneal injection once daily for 40 days after being fed a high fat diet plus 10% high fructose liquid (HFD+HFL) for 8 weeks. Xyloketal B significantly improved HFD+HFL-induced hepatic histological lesions and attenuated lipid and glucose accumulation in the blood as well as lipid accumulation in the liver. Xyloketal B increased the expression of CPT1A, and decreased the expression of SREBP-1c and its downstream targeting enzymes such as ACC1, ACL, and FAS. Xyloketal B also significantly reduced lipid accumulation in HepG2 cells treated with free fatty acids (FFAs). These data suggested that xyloketal B has lipid-lowering effects via the SREBP-1c pathway that regulate lipid metabolism. Thus, targeting SREBP-1c activation with xyloketal B may be a promising novel approach for NAFLD treatment. Full article
Figures

Figure 1

Open AccessArticle Pharmacophore-Based Virtual Screening of Novel Inhibitors and Docking Analysis for CYP51A from Penicillium italicum
Mar. Drugs 2017, 15(4), 107; doi:10.3390/md15040107
Received: 10 February 2017 / Revised: 24 March 2017 / Accepted: 30 March 2017 / Published: 5 April 2017
PDF Full-text (1199 KB) | HTML Full-text | XML Full-text
Abstract
Sterol 14α-demethylases from Cytochrome P450 family (CYP51s) are essential enzymes in sterol biosynthesis and well-known as the target of antifungal drugs. The 3D structure of CYP51A from Penicillium italicum (PiCYP51A) was constructed through homology modeling based on the crystal structure of human CYP51A
[...] Read more.
Sterol 14α-demethylases from Cytochrome P450 family (CYP51s) are essential enzymes in sterol biosynthesis and well-known as the target of antifungal drugs. The 3D structure of CYP51A from Penicillium italicum (PiCYP51A) was constructed through homology modeling based on the crystal structure of human CYP51A (PDB: 3LD6). Molecular dynamics (MD) simulation was operated to relax the initial model and followed by quality assessment using PROCHECK program. On the basis of the docking information on the currently available CYP51s with the patent demethylase inhibitors (DMIs), pharmacophore-based virtual screening combined with docking analysis was performed to pick out twelve new compounds from ZINC database. Six hits revealed in the ligand database suggested potential ability to inhibit PiCYP51A. Compared to patent fungicide triazolone, the top three lead compounds had similar or higher affinity with the target enzyme, and accordingly, exhibited comparable or lower EC50 values to P. italicum isolates. The results could provide references for de novo antifungal drug design. Full article
Figures

Figure 1

Journal Contact

MDPI AG
Marine Drugs Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: 
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Marine Drugs Edit a special issue Review for Marine Drugs
logo
loading...
Back to Top